Clinical trials recruiting for Extensive-stage Small Cell Lung Cancer (ES-SCLC)

Phase breakdown

Drugs and treatments being studied

Where trials are recruiting (top US states)

Top cities

Self-screener

Recruiting trials

• A Study of Ivonescimab in First-Line ES-SCLC
  NCT07245446 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 3 locations
• A Study to Evaluate DJI136, a DLL3-targeted CAR-T Therapy
  NCT07564401 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 6 locations
• Atezolizumab and Rechallenge Chemotherapy in Relapsed Patients With Extensive-stage Small Cell Lung Cancer (ES-SCLC).
  NCT06663098 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 25 locations
• Iadademstat + SBRT With Atezo in ES-SCLC
  NCT07113691 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Metronomic Oral Paclitaxel Plus PD-1/ PD-L1 Inhibitor Maintenance in Advanced Lung Cancer (PULSE Study)
  NCT07744698 · Phase: Phase 4 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 1 location
• Post-line Treatment With Teniposide for c-Myc-driven Extensive-stage Small Cell Lung Cancer
  NCT06758700 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 1 location
• Second-line Immunotherapy for ES-SCLC
  NCT06853678 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Sintilimab Combined With Tafolecimab and Chemotherapy as First-Line Treatment for Extensive-Stage Small Cell Lung Cancer
  NCT07061535 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 5 locations
• Small Extracellular Vesicle miRNAs as Predictive Biomarkers for Immunochemotherapy Efficacy in Extensive-stage Small Cell Lung Cancer
  NCT07070011 · Phase: Not specified · Ages: 45 Years to 80 Years · Sex: All (male and female) · 1 location
• Study of Sacituzumab Govitecan Versus Standard of Care in Participants With Previously Treated Extensive Stage Small Cell Lung Cancer
  NCT06801834 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 220 locations
• Study of Sacituzumab Govitecan With Atezolizumab/Durvalumab as Maintenance Therapy for Extensive-Stage Small Cell Lung Cancer
  NCT07339059 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Tislelizumab Combined With Chemotherapy Followed by Thoracic Consolidation Radiotherapy in the First-line Treatment of Extensive Stage Small Cell Lung Cancer
  NCT07425795 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 1 location
• Tislelizumab Combined With Chemotherapy and Relayed Radiotherapy in First-line Treatment of ES-SCLC
  NCT06838208 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location

Related conditions

Trials recruiting for Extensive-stage Small Cell Lung Cancer (ES-SCLC) often also study these conditions. Each links to its own recruiting-trial list.

Common questions

Are these trials free to join?

Study-related care in a clinical trial is usually provided at no cost to participants, and some trials reimburse travel. Costs vary by study - the trial team will explain what is and is not covered. Confirm this directly with them.

How do I know if I am eligible for Extensive-stage Small Cell Lung Cancer (ES-SCLC) trials?

Each trial lists inclusion and exclusion criteria. The screener above checks stated age and sex only. The full eligibility (your medical history, current medications, test results) is assessed by the study team. Open any trial to read its criteria, then contact the site.

Is this list complete?

No. For the full list, search ClinicalTrials.gov.